Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews.
Cannabinoids
Cannabis
Evidence mapping
Evidence synthesis
Medical marijuana
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
15 Jan 2020
15 Jan 2020
Historique:
received:
27
03
2019
accepted:
22
12
2019
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
30
7
2020
Statut:
epublish
Résumé
Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps. We searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios. A total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores. Evidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data.
Sections du résumé
BACKGROUND
BACKGROUND
Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evidence maps.
METHODS
METHODS
We searched PubMed, EMBASE, The Cochrane Library and CINAHL, to identify systematic reviews (SRs) published from their inception up to December 2017. Two authors assessed eligibility and extracted data independently. We assessed methodological quality of the included SRs using the AMSTAR tool. To illustrate the extent of use of medical cannabis, we organized the results according to identified PICO questions using bubble plots corresponding to different clinical scenarios.
RESULTS
RESULTS
A total of 44 SRs published between 2001 and 2017 were included in this evidence mapping with data from 158 individual studies. We extracted 96 PICO questions in the following medical conditions: multiple sclerosis, movement disorders (e.g. Tourette Syndrome, Parkinson Disease), psychiatry conditions, Alzheimer disease, epilepsy, acute and chronic pain, cancer, neuropathic pain, symptoms related to cancer (e.g. emesis and anorexia related with chemotherapy), rheumatic disorders, HIV-related symptoms, glaucoma, and COPD. The evidence about these conditions is heterogeneous regarding the conclusions and the quality of the individual primary studies. The quality of the SRs was moderate to high according to AMSTAR scores.
CONCLUSIONS
CONCLUSIONS
Evidence on medical uses of cannabis is broad. However, due to methodological limitations, conclusions were weak in most of the assessed comparisons. Evidence mapping methodology is useful to perform an overview of available research, since it is possible to systematically describe the extent and distribution of evidence, and to organize scattered data.
Identifiants
pubmed: 32020875
doi: 10.1186/s12906-019-2803-2
pii: 10.1186/s12906-019-2803-2
pmc: PMC7076827
doi:
Substances chimiques
Cannabinoids
0
Medical Marijuana
0
Types de publication
Journal Article
Review
Langues
eng
Pagination
12Références
BMC Med Res Methodol. 2011 Jun 17;11:92
pubmed: 21682870
J Oral Facial Pain Headache. 2015 Winter;29(1):7-14
pubmed: 25635955
Arch Phys Med Rehabil. 2016 Aug;97(8):1381-1391.e1
pubmed: 26797114
Curr Treat Options Neurol. 2014 Oct;16(10):314
pubmed: 25143234
Can Fam Physician. 2015 Aug;61(8):e372-81
pubmed: 26505059
Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007204
pubmed: 19370677
BMC Neurol. 2009 Dec 04;9:59
pubmed: 19961570
J Crohns Colitis. 2015 Jan;9(1):86-106
pubmed: 25518050
Int J Drug Policy. 2013 Nov;24(6):511-6
pubmed: 24095000
JAMA. 2015 Jun 23-30;313(24):2474-83
pubmed: 26103031
Cochrane Database Syst Rev. 2003;(4):CD001332
pubmed: 14583932
J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210
pubmed: 24175484
Arch Phys Med Rehabil. 2010 May;91(5):816-31
pubmed: 20434623
Pharmacotherapy. 2013 Feb;33(2):195-209
pubmed: 23386598
Phys Ther. 2017 Feb 1;97(2):239-248
pubmed: 27660328
Cannabis Cannabinoid Res. 2016 Jun 01;1(1):131-138
pubmed: 28861489
P T. 2017 Mar;42(3):180-188
pubmed: 28250701
Mult Scler. 2016 Oct;22(11):1386-1396
pubmed: 27207462
Br J Clin Pharmacol. 2011 Nov;72(5):735-44
pubmed: 21426373
Ann Med. 2016;48(3):128-41
pubmed: 26912385
Planta. 2019 Jun;249(6):1681-1694
pubmed: 30877436
Pain Pract. 2014 Feb;14(2):167-84
pubmed: 23534696
CMAJ. 2008 Jun 17;178(13):1669-78
pubmed: 18559804
BMJ. 2001 Jul 7;323(7303):16-21
pubmed: 11440936
Schmerz. 2016 Feb;30(1):62-88
pubmed: 26830780
Cochrane Database Syst Rev. 2009 Oct 07;(4):CD006565
pubmed: 19821373
Cochrane Database Syst Rev. 2015 Nov 12;(11):CD009464
pubmed: 26561338
Cochrane Database Syst Rev. 2014 Mar 05;(3):CD009270
pubmed: 24595491
Neurology. 2014 Apr 29;82(17):1556-63
pubmed: 24778283
Schmerz. 2016 Feb;30(1):47-61
pubmed: 26767993
J Pain. 2015 Dec;16(12):1221-1232
pubmed: 26362106
PLoS One. 2010 Dec 28;5(12):e14433
pubmed: 21203440
Schmerz. 2016 Feb;30(1):25-36
pubmed: 26809975
BMC Med Res Methodol. 2007 Feb 15;7:10
pubmed: 17302989
Am J Ophthalmol. 2017 May;177:xv-xviii
pubmed: 28342528
Epidemiol Prev. 2017 Sep-Dec;41(5-6):279-293
pubmed: 29119763
Evid Based Complement Alternat Med. 2013;2013:149468
pubmed: 23861696
BMC Med Res Methodol. 2017 Sep 7;17(1):135
pubmed: 28882125
BMJ. 2001 Jul 7;323(7303):13-6
pubmed: 11440935
Cochrane Database Syst Rev. 2012 Apr 18;(4):CD004157
pubmed: 22513921
N Engl J Med. 2014 Jun 5;370(23):2219-27
pubmed: 24897085
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD005175
pubmed: 23633327
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
Schmerz. 2016 Feb;30(1):37-46
pubmed: 26809974
Drugs. 2013 Oct;73(15):1711-22
pubmed: 24085618
J Neuroimmune Pharmacol. 2015 Jun;10(2):293-301
pubmed: 25796592
Cochrane Database Syst Rev. 2016 Feb 02;2:CD007786
pubmed: 26836199
Int J Drug Policy. 2017 Apr;42:30-35
pubmed: 28189912
Arthritis Care Res (Hoboken). 2016 May;68(5):681-8
pubmed: 26548380
Life Sci. 2019 May 1;224:120-127
pubmed: 30910646
Eur J Cancer Care (Engl). 2008 Sep;17(5):431-43
pubmed: 18625004
Mayo Clin Proc. 2012 Feb;87(2):172-86
pubmed: 22305029
Brain Inj. 2010;24(5):706-21
pubmed: 20376996
Acta Anaesthesiol Scand. 2017 Mar;61(3):268-280
pubmed: 28090652
Ageing Res Rev. 2014 Mar;14:56-64
pubmed: 24509411
Lancet Neurol. 2015 Feb;14(2):162-73
pubmed: 25575710
Pain Med. 2009 Nov;10(8):1353-68
pubmed: 19732371
Clin Transl Oncol. 2019 Oct;21(10):1398-1412
pubmed: 30875063
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008921
pubmed: 22258992
Curr Med Res Opin. 2007 Jan;23(1):17-24
pubmed: 17257464
BJU Int. 2017 Apr;119(4):515-521
pubmed: 28058780
SAGE Open Med. 2018 Oct 03;6:2050312118801710
pubmed: 30302249
EMBO Rep. 2015 Feb;16(2):130-2
pubmed: 25576303
Trends Pharmacol Sci. 2017 Mar;38(3):195-198
pubmed: 28095988